Initial Statement of Beneficial Ownership (3)
April 23 2020 - 6:15PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Innoviva, Inc. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/22/2020
|
3. Issuer Name and Ticker or Trading Symbol
Entasis Therapeutics Holdings Inc. [ETTX]
|
(Last)
(First)
(Middle)
1350 OLD BAYSHORE HIGHWAY SUITE 400 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
BURLINGAME, CA 94010
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 1322510 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Warrants to Purchase Common Stock | 4/22/2020 | 4/22/2025 | Common Stock | 1322510 (1) | $2.50 | D | |
Explanation of Responses: |
(1) | As reflected in the Schedule 13D filed by Innoviva, Inc. (the "Reporting Person") with the U.S. Securities and Exchange Commission on April 23, 2020 (the "Schedule 13D"), in connection with an initial closing that occurred on April 22, 2020 pursuant to a securities purchase agreement, dated as of April 12, 2020 (the "Purchase Agreement" and, such closing, the "Initial Closing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and the Reporting Person, the Reporting Person acquired 1,322,510 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 1,322,510 Shares ("Warrants") as set forth in this Form 3. As a result of the Initial Closing, the Reporting Person beneficially owns 2,645,020 Shares. The Schedule 13D filed by the Reporting Person is incorporated by reference in this Form 3; any description herein of the Schedule 13D is qualified in its entirety by reference to the Schedule 13D so filed by the Reporting Person. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Innoviva, Inc. 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME, CA 94010 |
| X |
|
|
Signatures
|
/s/ Geoffrey Hulme | | 4/23/2020 |
**Signature of Reporting Person | Date |
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024